Sign in
Taking people in United StatesPhase 2

Long-term study of ORX750 in narcolepsy and idiopathic hypersomnia

Tests ORX750 over time in adults with narcolepsy or idiopathic hypersomnia.

Key facts

Who runs it
Centessa Pharmaceuticals (UK) Limited
Where
Abington, Atlanta, Auburn, Austin, Cincinnati, Denver, Dublin, El Paso, Henderson, Huntersville, Miami, North Charleston, Orlando, Santa Ana, Sterling Heights, Willow Grove, and Winter Park, United StatesSee the 19 sitesAlso in 4 other countries, 9 sites
Registry title
A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
Status
Recruiting
Phase
Phase 2
People taking part
90 people, planned
Started
12 Aug 2025
Planned end
30 Apr 2026
Type of study
Interventional, 3 groups
Treatments tested
  • ORX750
Record updated
16 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with narcolepsy type 1, narcolepsy type 2 or idiopathic hypersomnia who completed the full treatment period of the earlier study ORX750-0201 (CRYSTAL-1). They will take ORX750 long term.

Age
18 Years to 65 Years
Sex
All
Disease stage
Narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) or idiopathic hypersomnia (IH), a condition with too much sleepiness without a known cause.
Earlier treatment
People must have completed the full treatment period in the parent study ORX750-0201 (CRYSTAL-1).

Main reasons for not taking part

  • A new disease or disorder that the study doctor thinks would stop the person from continuing the study
  • Not able to stop medicines the study does not allow, including medicines for narcolepsy or idiopathic hypersomnia
  • Not willing or able to follow the study rules

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Diagnosis of narcolepsy (NT1 or NT2) or IH who was eligible for and completed the full treatment period in the eligible parent study ORX750-0201 (CRYSTAL-1)
  • Is willing and able to adhere to additional protocol requirements

Who cannot take part

  • Unable to refrain from excluded medications, including those used for treatment of narcolepsy or idiopathic hypersomnia
  • Development of any new disease/disorder that in the opinion of the investigator would make the participant unable to continue the study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

Also in 4 other countries, 9 sites

  • Abington, PennsylvaniaAbington, United StatesContact: Orexin Centessa Program LeadTaking people
  • Atlanta, GeorgiaAtlanta, United StatesContact: Orexin Centessa Program LeadTaking people
  • Stockbridge, GAAtlanta, United StatesContact: Orexin Centessa Program LeadTaking people
  • Auburn, AlabamaAuburn, United StatesContact: Orexin Centessa Program LeadTaking people
  • Austin, TexasAustin, United StatesContact: Orexin Centessa Program LeadTaking people
  • Cincinnati, OhioCincinnati, United StatesContact: Orexin Centessa Program LeadTaking people
  • Denver, North CarolinaDenver, United StatesContact: Orexin Centessa Program LeadTaking people
  • DublinDublin, United StatesContact: Orexin Centessa Program LeadTaking people
  • El Paso, TexasEl Paso, United StatesContact: Orexin Centessa Program LeadTaking people
  • Hendersen, NavadaHenderson, United StatesContact: Orexin Centessa Program LeadTaking people
  • Henderson, NevadaHenderson, United StatesContact: Orexin Centessa Program LeadTaking people
  • Huntersville, North CarolinaHuntersville, United StatesContact: Orexin Centessa Program LeadTaking people
  • Miami, FloridaMiami, United StatesContact: Orexin Centessa Program LeadTaking people
  • North Charleston, South CarolinaNorth Charleston, United StatesContact: Orexin Centessa Program LeadTaking people
  • Orlando, FloridaOrlando, United StatesContact: Orexin Centessa Program LeadTaking people
  • Santa Ana, CaliforniaSanta Ana, United StatesContact: Orexin Centessa Program LeadTaking people
  • Sterling Heights, MichiganSterling Heights, United StatesContact: Orexin Centessa Program LeadTaking people
  • Willow Grove, PennsylvaniaWillow Grove, United StatesContact: Orexin Centessa Program LeadTaking people
  • Winter Park, FLWinter Park, United StatesContact: Orexin Centessa Program LeadTaking people

About the trial

What the trial wants to find out

This study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).

The 3 groups in the trial

  • Narcolepsy Type 1Treatment being tested

    Narcolepsy Type 1 (Open Label)

    Treatment: ORX750

  • Narcolepsy Type 2Treatment being tested

    Narcolepsy Type 2 (Open Label)

    Treatment: ORX750

  • Idiopathic HypersomniaTreatment being tested

    Idiopathic Hypersomnia (Open Label)

    Treatment: ORX750

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 2, Long-term Extension Study of the Safety and Efficacy of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia Who Completed a Sponsored ORX750 Clinical Trial
Plain-language title
Long-term study of ORX750 in narcolepsy and idiopathic hypersomniaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07096674, who can take part
Record updated
16 April 2026